rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
3
|
pubmed:dateCreated |
2008-10-9
|
pubmed:abstractText |
We report the case of a 58-year-old man with multiple myeloma stage III A who received tandem autologous stem cell transplantation after induction by two courses of VAD and three cycles of bortezomib-dexamethasone, due to progression under chemotherapy. The second transplantation was complicated by severe hepatic veno-occlusive disease (HVOD). The patient received defibrotide with total recovery. The occurence of HVOD after conditioning by melphalan is uncommon and the role of bortezomib was questioned.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
1865-3774
|
pubmed:author |
|
pubmed:issnType |
Electronic
|
pubmed:volume |
88
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
291-3
|
pubmed:meshHeading |
pubmed-meshheading:18696182-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18696182-Boronic Acids,
pubmed-meshheading:18696182-Dexamethasone,
pubmed-meshheading:18696182-Doxorubicin,
pubmed-meshheading:18696182-Etoposide,
pubmed-meshheading:18696182-Hepatic Veno-Occlusive Disease,
pubmed-meshheading:18696182-Humans,
pubmed-meshheading:18696182-Male,
pubmed-meshheading:18696182-Melphalan,
pubmed-meshheading:18696182-Middle Aged,
pubmed-meshheading:18696182-Multiple Myeloma,
pubmed-meshheading:18696182-Myeloablative Agonists,
pubmed-meshheading:18696182-Pyrazines,
pubmed-meshheading:18696182-Stem Cell Transplantation,
pubmed-meshheading:18696182-Transplantation, Autologous,
pubmed-meshheading:18696182-Transplantation Conditioning
|
pubmed:year |
2008
|
pubmed:articleTitle |
Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan.
|
pubmed:affiliation |
Department of Medical Oncology, Centre Léon Bérard, Lyon, France. LABIDI@lyon.fnclcc.fr
|
pubmed:publicationType |
Journal Article,
Case Reports
|